| NCT06509009 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Nasopharyngeal Carcinoma by AJCC V8 Stage | 2024-08-30 | PHASE2 |
| NCT00985998 | Biotech Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 2009-09 | PHASE1 |
| NCT04949503 | Biotech Pharmaceutical Co., Ltd. | Locally Advanced Head and Neck Squamous Cell Carcinoma | 2021-10-08 | |
| NCT01232374 | Biotech Pharmaceutical Co., Ltd. | Squamous Cell Carcinoma | 2010-09 | PHASE2 |
| NCT06048913 | The First Affiliated Hospital with Nanjing Medical University | Esophageal Carcinoma | 2020-12-01 | PHASE2 |
| NCT01688700 | Zhejiang Cancer Hospital | Esophageal Squamous Cell Carcinoma Resectable | 2012-09 | PHASE2 |
| NCT02945267 | Chinese PLA General Hospital | Unresectable Pancreatic Cancer | 2016-09 | PHASE4 |
| NCT01336049 | Peking University | Esophageal Squamous Cell Cancer | 2011-03 | PHASE2 |
| NCT06404840 | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 2022-05-06 | PHASE2 |
| NCT06879691 | Biotech Pharmaceutical Co., Ltd.|Baotou Cancer Hospital | Head and Neck Cancer | 2021-05-15 | PHASE4 |
| NCT02409186 | Shandong Cancer Hospital and Institute | Prosthesis Survival | 2015-03 | PHASE3 |
| NCT06490341 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Locally Advanced Nasopharyngeal Carcinoma | 2024-07-20 | PHASE2 |
| NCT01402180 | Fudan University|Shanghai Chest Hospital|Shanghai Pulmonary Hospital, Shanghai, China|RenJi Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Esophageal Squamous Cell Carcinoma | 2010-12 | PHASE2|PHASE3 |
| NCT02395068 | Biotech Pharmaceutical Co., Ltd. | Solid Tumors | 2012-11 | PHASE1 |
| NCT03469531 | Zhujiang Hospital | Neoplasms|Cervical Adenosquamous Cell Carcinoma|Cervical Squamous Cell Carcinoma in Situ|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage IVA Cervical Cancer | 2018-03-20 | PHASE2 |
| NCT04456322 | Sun Yat-sen University | Nasopharyngeal Carcinoma | 2020-08-17 | PHASE3 |
| NCT01145170 | Eurofarma Laboratorios S.A.|Centro de Immunologia Molecular, Cuba | Diffuse Intrinsic Brainstem Gliomas | 2011-03 | PHASE2 |
| NCT01249352 | Eurofarma Laboratorios S.A. | Esophageal Cancer|Adenocarcinoma | 2009-01 | PHASE2|PHASE3 |
| NCT06422156 | Peking University Third Hospital|Biotech Pharmaceutical Co., Ltd. | Advanced Pancreatic Cancer | 2024-06-01 | PHASE2 |
| NCT07535567 | Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University | Head and Neck Squamous Cell Carcinoma | 2026-05-05 | PHASE2|PHASE3 |
| NCT07333274 | Shandong Cancer Hospital and Institute | Head & Neck Squamous Cell Carcinoma|Head & Neck Cancer | 2026-01-05 | PHASE3 |
| NCT00600054 | YM BioSciences | Recurrent Diffuse Pontine Gliomas | 2007-10 | PHASE2 |
| NCT01516996 | The Second People´s Hospital of Sichuan|Biotech Pharmaceutical Co., Ltd. | Oropharyngeal Cancer|Hypopharyngeal Cancer | 2012-03 | PHASE2 |
| NCT01345084 | Eurofarma Laboratorios S.A. | Carcinoma|Head and Neck Cancer | 2013-11 | PHASE3 |
| NCT01393080 | Tianjin Medical University Cancer Institute and Hospital|Biotech Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 2011-03 | NA |
| NCT06676722 | The First Affiliated Hospital of Xiamen University | Nasopharyngeal Cancinoma (NPC)|SBRT|Immunotherapy | 2024-11-05 | PHASE2 |
| NCT07070479 | Ming-Yuan Chen | Recurrent or Metastatic Nasopharyngeal Carcinoma | 2025-06-24 | PHASE2 |
| NCT01425736 | Wei Guo|Sun Yat-sen University | Head and Neck Squamous Cell Carcinoma | 2009-01 | PHASE2 |
| NCT06363084 | Ruijin Hospital | Resectable Pancreatic Cancer | 2016-05-01 | |
| NCT00950417 | Biotech Pharmaceutical Co., Ltd. | Advanced Esophageal | 2009-07 | PHASE1 |
| NCT07353723 | Tang-Du Hospital | Head & Neck Cancer | 2025-11-15 | PHASE2 |
| NCT01393184 | Peking University|Biotech Pharmaceutical Co., Ltd. | SCCHN | 2011-03 | PHASE2 |
| NCT02549261 | Biotech Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 2011-03 | NA |
| NCT03666221 | Fujian Cancer Hospital|Sun Yat-sen University|Jiangxi Provincial Cancer Hospital|Zhejiang Cancer Hospital|Fujian Medical University Union Hospital | Recurrent Nasopharyngeal Carcinoma | 2014-11-01 | PHASE2 |
| NCT03554889 | Hangzhou Cancer Hospital|Shanghai bokang bioengineering co., LTD | Advanced Cancer|ADCC|NK Cell Mediated Immunity|Nimotuzumab|Adaptive Transfer | 2018-08-01 | PHASE1 |
| NCT07277452 | The First Affiliated Hospital with Nanjing Medical University|Peking University Cancer Hospital & Institute | Pancreatic Cancer, Adult | 2025-12-10 | PHASE2 |
| NCT06022276 | Tianjin Medical University Second Hospital | Solid Tumor|EGFR Amplification | 2022-12-01 | NA |
| NCT06333821 | Biotech Pharmaceutical Co., Ltd. | Cervical Cancer | 2024-04-01 | PHASE3 |
| NCT04976478 | Peking University Third Hospital | Cervical Squamous Cell Carcinoma | 2021-07 | |
| NCT00972465 | Peking University|Biotech Pharmaceutical Co., Ltd. | Advanced Colorectal Cancer | 2009-06 | PHASE2 |
| NCT06718205 | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer | 2023-03-08 | PHASE2 |
| NCT04475016 | Sun Yat-sen University | Penile Cancer | 2020-08-12 | PHASE2 |
| NCT06343116 | Biotech Pharmaceutical Co., Ltd. | Refractory Metastatic Colorectal Cancer | 2024-04 | PHASE3 |
| NCT02395016 | Biotech Pharmaceutical Co., Ltd.|NanJing PLA 81 Hospital|Fudan University | Pancreatic Cancer | 2015-04 | PHASE3 |
| NCT02705612 | Air Force Military Medical University, China | Cervical Cancer | 2015-09 | PHASE2 |
| NCT02272699 | Peking University | Esophageal Squamous Cell Carcinoma | 2014-11 | PHASE2|PHASE3 |
| NCT02095119 | National Institute of Cancerología | Uterine Cervical Cancer | 2008-07 | PHASE1|PHASE2 |
| NCT03574402 | Guangdong Association of Clinical Trials|Chinese Thoracic Oncology Group | Carcinoma, Non-Small-Cell Lung | 2018-07-09 | PHASE2 |
| NCT05355168 | Anhui Provincial Hospital | Toxicity, Drug | 2021-11-01 | PHASE2 |
| NCT02039791 | Biotech Pharmaceutical Co., Ltd. | Cervical Cancer | 2013-01 | PHASE2 |
| NCT03388372 | Biotech Pharmaceutical Co., Ltd.|Sun Yat-sen University | Glioblastoma | 2010-08-18 | PHASE2 |
| NCT01939054 | Chinese Academy of Medical Sciences|Biotech Pharmaceutical Co., Ltd. | Breast Cancer | 2013-09 | PHASE2 |
| NCT05606263 | Xi´an Jiaotong University | Cervical Cancer | 2022-11-01 | PHASE2 |
| NCT00561990 | Oncoscience AG|Marienhospital Herne|University of Kiel|Gemeinschaftspraxis für H?matologie und Onkologie, K?ln, Germany|Onkologisches Zentrum III, Medizinische Klinik, Mannheim, Germany|Onkologische Gemeinschaftspraxis, Mülheim, Germany|II. Medizinische Klinik u. Poliklinik, Klinikum rechts der Isar, München, Germany|H?matologisch-Onkologische Schwerpunktpraxis, Münster, Germany|Praxis für Internistische Onkologie und H?matologie, Recklinghausen, Germany | Pancreatic Cancer, Advanced or Metastatic | 2007-09 | PHASE2|PHASE3 |
| NCT04207918 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer|Chemoradiotherapy|Nimotuzumab|Unresectable Malignant Neoplasm | 2019-11-14 | PHASE2 |
| NCT02611700 | Biotech Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinomas | 2015-11 | PHASE3 |
| NCT04833205 | Hui Bu | Leptomeningeal Metastasis|Lung Cancer | 2021-04-19 | PHASE2 |
| NCT04508816 | Fudan University | Nasopharyngeal Carcinoma | 2016-01-01 | PHASE2 |
| NCT06912711 | Sun Yat-sen University | Nasopharyngeal Carcinoma | 2025-05-16 | PHASE2 |
| NCT07312578 | Peking University | Esophageal Squamous Cell Carcinoma | 2025-11-01 | PHASE2 |
| NCT06770452 | Zhejiang University | Metastatic Pancreatic Carcinoma | 2025-03-25 | PHASE2 |
| NCT02293356 | Biotech Pharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma | 2015-08 | PHASE4 |
| NCT00983047 | Biotech Pharmaceutical Co., Ltd. | Advanced Non-Small Cell Lung Cancer | 2009-08 | PHASE2 |
| NCT03400592 | Peking University|Chinese PLA General Hospital | Stomach Neoplasms | 2015-06 | PHASE2 |
| NCT01074021 | Biotech Pharmaceutical Co., Ltd. | Nasopharyngeal Cancer | 2009-10 | PHASE3 |
| NCT01382745 | Dr. Te Vuong|YM BioSciences | Squamous Cell Carcinoma of Anal Canal | 2012-01 | PHASE2 |
| NCT01861223 | Samsung Medical Center | NSCLC | 2013-05 | PHASE1|PHASE2 |
| NCT06781073 | Biotech Pharmaceutical Co., Ltd. | Cervical Squamous Cell Carcinoma|Persistent | 2017-07-06 | PHASE3 |
| NCT01498562 | Yonsei University | Non Small Cell Lung Cancer (NSCLC) | 2011-12 | PHASE2 |
| NCT06413017 | Tianjin Medical University Cancer Institute and Hospital | HCC | 2023-08-31 | PHASE2 |
| NCT05978050 | Biotech Pharmaceutical Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 2024-08-01 | PHASE3 |
| NCT05717790 | Fourth Affiliated Hospital of Guangxi Medical University|People´s Hospital of Baise|Second Affiliated Hospital of Guangzhou Medical University|People´s Hospital of Guangxi Zhuang Autonomous Region|Guilin Medical University, China|LiuZhou People´s Hospital|The First People´s Hospital of Qinzhou|Wuzhou Red Cross Hospital|Youjiang Medical College for Nationalities | Nasopharyngeal Carcinoma by AJCC V8 Stage | 2022-12-01 | NA |
| NCT01463605 | Chinese Academy of Medical Sciences | Esophageal Cancer | 2011-06 | PHASE2 |
| NCT05316480 | Fudan University | Pancreatic Neuroendocrine Neoplasm | 2022-05-01 | PHASE2 |
| NCT01813253 | Kuhnil Pharmaceutical Co., Ltd.|Daiichi Sankyo Co., Ltd. | Gastric Cancer|Gastroesophageal Junction Cancer | 2013-05-13 | PHASE3 |
| NCT03766178 | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 2021-09 | PHASE2 |
| NCT00957086 | National Cancer Centre, Singapore|National Medical Research Council (NMRC), Singapore|Innogene Kalbiotech Pte. Ltd | Carcinoma, Squamous Cell of Head and Neck | 2009-08-13 | PHASE3 |
| NCT03025958 | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 2017-03-13 | PHASE2 |
| NCT04367909 | Xin-Hua Xu | Oral Squamous Cell Carcinoma | 2020-06-21 | PHASE2 |
| NCT00872482 | YM BioSciences|CIMYM BioSciences | Metastatic Non-Small Cell Lung Cancer | 2009-04 | PHASE2 |
| NCT06259721 | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 2024-02-10 | PHASE2 |
| NCT03620032 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|University of Roma La Sapienza|Johannes Gutenberg University Mainz|Fondazione IRCCS Ca´ Granda, Ospedale Maggiore Policlinico|Wuerzburg University Hospital | Diffuse Intrinsic Pontine Glioma | 2015-11-02 | PHASE2 |
| NCT05024019 | Eye & ENT Hospital of Fudan University | Head and Neck Squamous Cell Carcinoma | 2021-08-21 | PHASE2 |
| NCT04821778 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer|Esophagogastric Junction Cancer|Chemoradiation|Targeted Therapy|Immunotherapy|Chemotherapy Effect | 2002-01-01 | PHASE3 |
| NCT02858206 | Chinese Academy of Medical Sciences|Hebei Medical University Fourth Hospital|Affiliated Hospital of Hebei University|Beijing Army General Hospital|Beijing Hospital|Peking University First Hospital|Tianjin Medical University Cancer Institute and Hospital|Henan Cancer Hospital|The Affiliated Hospital of Inner Mongolia Medical University|The First Affiliated Hospital with Nanjing Medical University|Fujian Cancer Hospital | Esophageal Neoplasms | 2016-06 | PHASE2 |
| NCT00753246 | Oncoscience AG|Neurological Clinic, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany|University of Bonn|Dep. of Neurosurgery and Policlinic, University Hospital, Dresden, Germany|Heinrich-Heine University, Duesseldorf|Johann Wolfgang Goethe University Hospital|University of Giessen|Universit?tsklinikum Hamburg-Eppendorf|University of Kiel|Dr. von Haunersches Children´s Medical Hospital, University of Munich, Germany|Universit?t Tübingen | Adults With Glioblastoma Multiforma | 2007-08 | PHASE3 |
| NCT02370849 | Chinese Academy of Medical Sciences | Stomach Neoplasms | 2009-10 | PHASE2 |
| NCT04821843 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer|Chemotherapy Effect|Chemoradiation|Surgery|Targeted Therapy|Immunotherapy|Esophagogastric Juction Cancer | 2002-01-01 | PHASE3 |
| NCT07310771 | Fujian Cancer Hospital | Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN) | 2026-01-10 | PHASE2 |
| NCT04882462 | The First Affiliated Hospital of Soochow University|Biotech Pharmaceutical Co., Ltd.|Cinda Biopharmaceutical (Suzhou) Co., Ltd. | Recurrent+Metastatic Head and Neck Squamous Cell Carcinoma | 2021-05-01 | PHASE2 |
| NCT06771596 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Uterine Cervical Neoplasms | 2021-05-12 | PHASE2 |
| NCT00369447 | YM BioSciences|CIMYM BioSciences | Non-small-cell Lung Cancer | 2009-03 | PHASE1|PHASE2 |
| NCT06722911 | Zhejiang Provincial People´s Hospital | Pancreatic Cancer Resectable | 2024-11-15 | PHASE2 |
| NCT02041819 | Zhejiang University | Squamous Cell Carcinoma of Esophagus | 2014-02 | PHASE2 |
| NCT03708822 | Sun Yat-sen University | Nasopharyngeal Carcinoma | 2018-10-15 | PHASE2 |
| NCT03557112 | Guiyang Medical University | Nasopharyngeal Carcinoma | 2018-06-01 | PHASE2 |
| NCT06409429 | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 2024-05-01 | PHASE2|PHASE3 |
| NCT01301612 | Eurofarma Laboratorios S.A. | Carcinoma|Adenocarcinoma|Uterine Cervix Adenosquamous Carcinoma | 2011-01 | PHASE2 |
| NCT00702481 | National Cancer Centre, Singapore|Innogene Kalbiotech Pte. Ltd | Head and Neck Cancer | 2008-04-28 | PHASE2 |
| NCT02591784 | Biotech Pharmaceutical Co., Ltd. | Esophageal | 2008-11 | PHASE2 |
| NCT06405685 | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 2023-04-27 | PHASE2 |
| NCT07053735 | Peking University First Hospital | Bladder (Urothelial, Transitional Cell) Cancer | 2025-06-30 | PHASE1 |
| NCT03837808 | Sun Yat-sen University|Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Guangdong Provincial People´s Hospital|First Affiliated Hospital, Sun Yat-Sen University | Nasopharyngeal Carcinoma|Nasopharyngeal Neoplasms|Nasopharyngeal Diseases|Head and Neck Neoplasm | 2019-04-11 | PHASE3 |
| NCT05351762 | Xijing Hospital | Head and Neck Squamous Cell Carcinoma | 2022-07-01 | PHASE2 |
| NCT07445048 | Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University | Head & Neck Squamous Cell Carcinoma|Head & Neck Cancer|Postoperative Adjuvant Treatment | 2026-03-04 | PHASE3 |
| NCT01180166 | Chinese Academy of Medical Sciences | Gastric Cancer|Concurrent Chemoradiotherapy | 2010-05 | PHASE2 |
| NCT03413579 | El Kendi Pharmaceuticals Manufacturing Company | Cervical Cancer | 2015-11 | PHASE3 |
| NCT01993784 | Peking University | Esophageal Squamous Cell Cancer | 2013-08 | PHASE1|PHASE2 |
| NCT06988956 | The First Affiliated Hospital with Nanjing Medical University | Esophageal Squamous Cell Carcinoma | 2024-03-31 | PHASE2 |
| NCT04678791 | Peking University Third Hospital | Cervical Squamous Cell Carcinoma | 2020-12 | NA |
| NCT00493857 | YM BioSciences | Colorectal Cancer | 2007-06 | PHASE2 |
| NCT00910117 | Fudan University | Head and Neck Cancer | 2009-05 | PHASE2 |
| NCT03915132 | Chinese Academy of Medical Sciences | Nasopharyngeal Carcinoma | 2019-05-01 | PHASE2 |
| NCT00561691 | Oncoscience AG|Children´s Medical Hospital, University of Bonn, Germany|University of Wuerzburg|Dept. of Statistics, University of Dortmund, Germany|CRM Biometrics GmbH|Heinrich-Heine University, Duesseldorf|Dr. von Haunersches Children´s Medical Hospital, University of Munich, Germany|Children´s Medical Hospital, University of Homburg+Saar, Homburg+Saar, Germany|Children´s Medical Hospital, Medical School Hannover, Hannover, Germany|Children´s Medical Hospital, University of Leipzig, Leipzig, Germany|Children´s Medical Hospital, University of Muenster, Muenster, Germany|Burdenko Neurosurgery Institute|Istituto Nazinonale Tumori, Div. of Paediatric Oncology,Milano, Italy | Diffuse Instrinsic Ponitine Glioma | 2006-04 | |
| NCT05772208 | Fudan University | Nasopharyngeal Carcinoma | 2022-01-01 | PHASE3 |
| NCT00369252 | YM BioSciences|CIMYM BioSciences | Advanced and+or Metastatic Solid Tumours | 2005-06 | PHASE1 |
| NCT01616849 | Sun Yat-sen University|Fujian Cancer Hospital|First People´s Hospital of Foshan|People´s Hospital of Guangxi Zhuang Autonomous Region|Guangxi Medical University|Guangzhou Medical University|Hubei Cancer Hospital|Hunan Provincial Cancer Hospital|Hangzhou Cancer Hospital|Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|Tongji Hospital|Jiangxi Provincial Cancer Hospital|Affiliated Cancer Hospital of Shantou University Medical College|Wuhan University|Zhejiang Cancer Hospital | Stage IV Nasopharyngeal Carcinoma | 2012-05 | PHASE2 |
| NCT02428764 | Sun Yat-sen University | Lung Cancer | 2015-04-01 | PHASE2 |
| NCT06938503 | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer, Adult | 2025-04-21 | PHASE2 |
| NCT06773130 | West China Hospital | Pancreatic Ductal Adenocarcinoma (PDAC) | 2025-02-10 | PHASE1|PHASE2 |
| NCT05278728 | Biotech Pharmaceutical Co., Ltd. | Colorectal Cancer | 2009-07 | PHASE1|PHASE2 |
| NCT01899118 | Zhejiang Cancer Hospital | Locally Advanced Rectal Cancer | 2013-04 | PHASE2 |
| NCT02012062 | Fudan University|Fujian Province Tumor Hospital|The First Affiliated Hospital of Xiamen University | Nasopharyngeal Carcinoma | 2012-07 | PHASE3 |
| NCT02034968 | Zhejiang University | Stage IV Esophageal Squamous Cell Carcinoma | 2014-02 | PHASE2 |
| NCT06389760 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Pancreatic Cancer | 2023-10-18 | PHASE2 |
| NCT06429839 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer|Nimotuzumab|Chemoradiotherapy|Chemotherapy|Immunotherapy | 2023-03-01 | PHASE2 |
| NCT02672241 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Childhood Brain Stem Neoplasm | 2016-01 | PHASE2 |
| NCT06410651 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer|Nimotuzumab|Chemoradiotherapy|Chemotherapy|Immunotherapy | 2023-03-01 | PHASE2 |
| NCT02011594 | Zhejiang University | Stage IV Esophageal Squamous Cell Carcinoma | 2014-01 | PHASE2 |
| NCT02083211 | National Institute of Cancerología|Laboratorios Pisa S.A. de C.V.|National Heart Institute, Mexico | Cervical Cancer Recurrent or Persistent|Palliative Treatment|Monoclonal Antibody in Cervical Cancer Treatment | 2010-07 | PHASE3 |
| NCT02947386 | Roswell Park Cancer Institute | EGFR Gene Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer | 2017-06-29 | PHASE1 |
| NCT07386704 | Peking University First Hospital | Pancreatic Cancer Non-resectable | 2025-12-09 | PHASE2 |